Drug intelligence / Profile preview

nifedipine + pentoxifylline

Development stage
Unknown
Lead developer
Bayer
Modality
Small Molecules
Administration
Topical, Oral
01

Overview

Nifedipine + pentoxifylline is a compounded combination drug, typically formulated as a topical cream or gel, designed to improve blood flow and alleviate symptoms associated with poor peripheral circulation. Nifedipine is a dihydropyridine calcium channel blocker that inhibits L-type voltage-gated calcium channels in vascular smooth muscle and myocardial cells, leading to vasodilation and reduced blood pressure. Pentoxifylline is a methylxanthine derivative that improves microcirculation by decreasing blood viscosity, increasing erythrocyte flexibility, reducing plasma fibrinogen levels, inhibiting neutrophil activation, and suppressing platelet aggregation; it also has anti-inflammatory effects. The combination acts synergistically to enhance peripheral perfusion and tissue oxygenation. This compounded medication is primarily used for conditions such as Raynaud’s phenomenon, intermittent claudication due to peripheral arterial disease (PAD), venous stasis ulcers, diabetic ulcers, chilblains (pernio), pressure ulcers, hypertension-related skin changes, and other disorders involving compromised microvascular circulation[1][3][4].

02

Targets

ADORA2A (Adenosine A₂A Receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)CACNA1D (Voltage-dependent L-type calcium channel subunit alpha-1D)CACNB2 (Voltage-gated calcium channel β2 subunit)PDE (Phosphodiesterase family)

Beyond the preview

Go deeper on nifedipine + pentoxifylline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nifedipine + pentoxifylline.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call